ASH 2023 | Serum biomarkers as predictors of disease progression in smoldering myeloma
Pre-disease stages like monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SM) have gained attention in clinical trials, such as in the iStopMM trial (NCT03327597). In this video, Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, introduces a study investigating changes in serum biomarkers that are predictive of disease progression in SM. The study reveals that a 0.4 g/dL change from the baseline in M spike or a 40% change in free light chain ratio within a year is associated with a shortened time to progression (TTP). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
